| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/01/2002 | US20020102542 Polypeptide for use in the treatment of cancer, autoimmune and viral diseases |
| 08/01/2002 | US20020102540 Functional dna clone for hepatitis c virus (hcv) and uses thereof |
| 08/01/2002 | US20020102535 Nucleic acid molecules and polypeptides for immune modulation |
| 08/01/2002 | US20020102311 Time-release agents; drug delivery |
| 08/01/2002 | US20020102296 Small particle liposome aerosols for delivery of anti-cancer drugs |
| 08/01/2002 | US20020102294 Aerosols comprising nanoparticle drugs |
| 08/01/2002 | US20020102285 Combination of acid protease enzymes and acidic buffers and uses thereof |
| 08/01/2002 | US20020102278 Cellular vaccines and immunotherapeutics and methods for their preparation |
| 08/01/2002 | US20020102276 For diagnosis, therapy and prophylaxis of Neisseria meningitidis infection; vaccine |
| 08/01/2002 | US20020102275 Transdermal administration of a botulinum toxin to a juvenile cerebral palsy patient for therapy |
| 08/01/2002 | US20020102274 Clostridial toxin therapy for Hashimoto's thyroiditis |
| 08/01/2002 | US20020102272 Composition for delivery of hematopoietic growth factor |
| 08/01/2002 | US20020102271 Target of RNAIII activating protein (TRAP) |
| 08/01/2002 | US20020102270 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 08/01/2002 | US20020102267 CLASP-5 transmembrane protein |
| 08/01/2002 | US20020102265 For diagnosis and imaging of cancer and tumor tissues |
| 08/01/2002 | US20020102263 Diagnosis and treatment of malignant neoplasms |
| 08/01/2002 | US20020102262 For prophhylaxis of Staphylococcus aureus infection |
| 08/01/2002 | US20020102261 Immunological control of beta-amyloid levels in vivo |
| 08/01/2002 | US20020102260 Screening an organism to determine presence or absence of VEGF-D-expressing tumor cells; selecting organism determined from screening to have tumor expressing VEGF-D; administering antagonist to prevent binding VEGF-D to its receptor |
| 08/01/2002 | US20020102259 Methods and compositions for stimulating CD 45 and thereby suppressing microglial activation associated with Alzheimer's disease |
| 08/01/2002 | US20020102258 Administering to a patient a therapeutic amount of TR2 antibody for therapy of pathological conditions |
| 08/01/2002 | US20020102256 Peptide and polypeptide inhibitors of complement C1s |
| 08/01/2002 | US20020102254 For diagnostic and therapeutic uses in cancer |
| 08/01/2002 | US20020102253 For use as anti-cancer agent and an immunosuppressive agent |
| 08/01/2002 | US20020102252 Novel isoforms of human pregnancy-associated protein-E |
| 08/01/2002 | US20020102251 Utilization of Wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence |
| 08/01/2002 | US20020102249 Administering to an individual in need of treatment thereof an effective amount of dermatan sulfate or chondroitin sulfate degrading enzyme to modulate fibrous tissue formation |
| 08/01/2002 | US20020102248 Modulating response to genotoxic stress |
| 08/01/2002 | US20020102247 For therapy of hyperproliferative disorders |
| 08/01/2002 | US20020102245 14-3-3sigma arrests the cell cycle |
| 08/01/2002 | US20020102242 Compositions and methods for administering pneumococcal DNA |
| 08/01/2002 | US20020102240 Administering therapeutically effective amount of beta 1C integrin reagent which inhibits cellular proliferation |
| 08/01/2002 | US20020102238 Reducing oxalate concentrations in an animal by administering formulation comprising a material selected from the group consisting of oxalate-degrading microbes and oxalate-degrading enzymes |
| 08/01/2002 | US20020102237 Compositions and methods for hepatitis treatment |
| 08/01/2002 | US20020102236 Liposomal interferon hybrid compositions |
| 08/01/2002 | US20020102235 Novel imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus |
| 08/01/2002 | US20020102233 For use in therapy of cancer |
| 08/01/2002 | US20020102232 Compositions and methods for induction of active autoimmunity |
| 08/01/2002 | US20020102231 Therapeutic uses of PAF-AH products in diabetes |
| 08/01/2002 | US20020102218 Stable, aerosolizable suspensions of proteins in ethanol |
| 08/01/2002 | DE10103695A1 Verwendung von Sialyltransferasen für die Diagnose und Therapie von Tumorerkrankungen Sialyltransferases of use in the diagnosis and therapy of tumor diseases |
| 08/01/2002 | DE10102878A1 Oligo- oder Polyalkylengekoppelte Thrombininhibitoren Oligo- or Polyalkylengekoppelte thrombin inhibitors |
| 08/01/2002 | DE10102784A1 Kosmetische oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes Cosmetic or pharmaceutical preparations for the treatment of epithelial integument |
| 08/01/2002 | DE10101890A1 HPV-spezifische Peptide, die die Bindung von HPV an die Wirtszelle blockieren HPV specific peptides that block the binding of HPV to the host cell |
| 08/01/2002 | DE10101793A1 Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen Use of SLPI in the treatment of chronic inflammatory bowel disease |
| 08/01/2002 | DE10101430A1 Lösliche cyclische Analoga Soluble cyclic analogues |
| 08/01/2002 | CA2563051A1 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | CA2442602A1 Probiotic compounds derived from lactobacillus casei strain ke01 |
| 08/01/2002 | CA2436139A1 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | CA2436076A1 Use of compositions containing pdgf-bb for promoting angiogenesis |
| 08/01/2002 | CA2435949A1 Biological organism for preparing pharmaceutical compositions for treating mammals |
| 08/01/2002 | CA2435888A1 Method of preparing biological materials and preparation produced using same |
| 08/01/2002 | CA2435776A1 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 08/01/2002 | CA2435672A1 Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses |
| 08/01/2002 | CA2435510A1 Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2.alpha.alphaactivity and methods of treating cancer |
| 08/01/2002 | CA2435124A1 Formulation of boronic acid compounds |
| 08/01/2002 | CA2435097A1 Peptides exibiting affinity for the viral protein gp120, and use of the se peptides |
| 08/01/2002 | CA2435047A1 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | CA2435038A1 Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics |
| 08/01/2002 | CA2434436A1 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 08/01/2002 | CA2434320A1 Chemokines as adjuvants of immune response |
| 08/01/2002 | CA2433838A1 Process for preparing particles |
| 08/01/2002 | CA2433834A1 Activatable cytolytic or drug delivery peptides and uses thereof |
| 08/01/2002 | CA2433681A1 Sulfatases and methods of use thereof |
| 08/01/2002 | CA2433680A1 Double-stranded rna-mediated gene suppression |
| 08/01/2002 | CA2433227A1 Specific human antibodies for selective cancer therapy |
| 08/01/2002 | CA2432988A1 Melanocortin receptor agonists |
| 08/01/2002 | CA2432985A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| 08/01/2002 | CA2432276A1 Regulation of cell growth by muc1 |
| 08/01/2002 | CA2432134A1 Adenylate cyclases |
| 08/01/2002 | CA2432096A1 Methods for preparing purified lipopeptides |
| 08/01/2002 | CA2431996A1 Melanocortin receptor agonists |
| 08/01/2002 | CA2431517A1 Polynucleotides encoding cellular transporters and methods of use thereof |
| 08/01/2002 | CA2431493A1 Aminoacyl trna synthetases |
| 08/01/2002 | CA2431177A1 Trem-1 splice variant for use in modifying immune responses |
| 08/01/2002 | CA2431144A1 Cell adhesion proteins |
| 08/01/2002 | CA2430762A1 Colon cancer marker |
| 08/01/2002 | CA2429034A1 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof |
| 08/01/2002 | CA2428084A1 Treatment of inflammatory bowel disease using growth factors |
| 08/01/2002 | CA2427647A1 Nucleic acid modification enzymes |
| 08/01/2002 | CA2427061A1 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | CA2426154A1 Agents and methods for promoting bone growth |
| 08/01/2002 | CA2426102A1 Method of diagnosing and treating cartilaginous disorders |
| 08/01/2002 | CA2425506A1 Methods for treating rheumatoid arthritis using il-17 antagonists |
| 08/01/2002 | CA2425149A1 Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents |
| 07/31/2002 | EP1227324A2 Har A polypeptides and nucleic acids and related methods and uses thereof |
| 07/31/2002 | EP1227160A1 Compounds modulating sister chromatid separation and method for identifying same |
| 07/31/2002 | EP1227156A2 A human protein kinase domain-containing protein |
| 07/31/2002 | EP1227155A1 Process for producing ubiquinone-10 |
| 07/31/2002 | EP1227153A2 Serpin from Bifidobacteria |
| 07/31/2002 | EP1227152A1 Bacterial strain and genome of bifidobacterium |
| 07/31/2002 | EP1227151A1 Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| 07/31/2002 | EP1227150A2 Androgen receptor complex-associated protein |
| 07/31/2002 | EP1227149A1 Novel protein and use thereof |
| 07/31/2002 | EP1227148A1 Gene ys68 concerning early hematopoiesis |
| 07/31/2002 | EP1227107A1 Selective acylation of E-amino groups |
| 07/31/2002 | EP1227106A1 Pro-apoptotic proteins and DNA molecules encoding them |
| 07/31/2002 | EP1227105A1 Ghsr ligand polypeptides and dnas thereof |
| 07/31/2002 | EP1226829A2 Stabilised liquid preparations of the protease or its proenzyme which activitate the blood coagulation factor VII |